The name is an acronym for N-(1-Amino-3,3-Dimethyl-1-oxoButan-2-yl)-1-(4-FlUoroBenzyl)-1H-INdAzole-3-CarboxAmide.
The (S)-enantiomer of ADB-FUBINACA is described in a 2009Pfizerpatent[6] and has been reported to be a potentagonist of theCB1 receptor and theCB2 receptor withEC50 values of 1.2 nM and 3.5 nM, respectively.[6][7] ADB-FUBINACA features a carboxamide group at the 3-indazole position, likeSDB-001 andSTS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs fromAB-FUBINACA only by the replacement of theisopropyl group with atert-butyl group.
An analogue of ADB-FUBINACA,ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.[9]
^Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids".Drug Testing and Analysis.15 (3):255–276.doi:10.1002/dta.3403.PMID36346325.
^Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (July 2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products".Forensic Toxicology.31 (2):223–240.doi:10.1007/s11419-013-0182-9.S2CID1279637.
^Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA".ACS Chemical Neuroscience.6 (9):1546–59.doi:10.1021/acschemneuro.5b00112.PMID26134475.
